h1

000851907 001__ 851907
000851907 005__ 20251103073640.0
000851907 0247_ $$2HSB$$aeva483339
000851907 0247_ $$2ISSN$$a0390-6078
000851907 0247_ $$2ISSN$$a1592-8721
000851907 0247_ $$2SCOPUS$$aSCOPUS:2-s2.0-85121037273
000851907 0247_ $$2WOS$$aWOS:000732456400011
000851907 0247_ $$2datacite_doi$$a10.18154/RWTH-CONV-248995
000851907 0247_ $$2doi$$a10.3324/haematol.2021.278722
000851907 0247_ $$2pmid$$apmid:34047178
000851907 037__ $$aRWTH-CONV-248995
000851907 041__ $$aEnglish
000851907 1001_ $$aKayser, Sabine$$b0$$eCorresponding author
000851907 245__ $$aCharacteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study$$honline
000851907 260__ $$aPavia$$bFerrata Storti Found$$c2021
000851907 264_1 $$2Crossref$$3online$$bFerrata Storti Foundation (Haematologica)$$c2021-05-27
000851907 3367_ $$00$$2EndNote$$aJournal Article
000851907 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal
000851907 3367_ $$2BibTeX$$aARTICLE
000851907 3367_ $$2DRIVER$$aarticle
000851907 3367_ $$2DataCite$$aOutput Types/Journal article
000851907 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000851907 542__ $$2Crossref$$i2021-05-27$$uhttps://creativecommons.org/licenses/by-nc/4.0/legalcode
000851907 591__ $$aFrance
000851907 591__ $$aGermany
000851907 7001_ $$aSchlenk, Richard F.$$b1
000851907 7001_ $$aLebon, Delphine$$b2
000851907 7001_ $$aCarre, Martin$$b3
000851907 7001_ $$aGötze, Katharina S.$$b4
000851907 7001_ $$aStölzel, Friedrich$$b5
000851907 7001_ $$aBerceanu, Ana$$b6
000851907 7001_ $$aSchäfer-Eckart, Kerstin$$b7
000851907 7001_ $$aPeterlin, Pierre$$b8
000851907 7001_ $$aHicheri, Yosr$$b9
000851907 7001_ $$aRahme, Ramy$$b10
000851907 7001_ $$aRaffoux, Emmanuel$$b11
000851907 7001_ $$aChermat, Fatiha$$b12
000851907 7001_ $$aKrause, Stefan W.$$b13
000851907 7001_ $$aAulitzky, Walter E.$$b14
000851907 7001_ $$aRigaudeau, Sophie$$b15
000851907 7001_ $$aNoppeney, Richard$$b16
000851907 7001_ $$aBerthon, Celine$$b17
000851907 7001_ $$aGörner, Martin$$b18
000851907 7001_ $$aJost, Edgar$$b19
000851907 7001_ $$aCarassou, Philippe$$b20
000851907 7001_ $$aKeller, Ulrich$$b21
000851907 7001_ $$aOrvain, Corentin$$b22
000851907 7001_ $$aBraun, Thorsten$$b23
000851907 7001_ $$aSaillard, Colombe$$b24
000851907 7001_ $$aArar, Ali$$b25
000851907 7001_ $$aKunzmann, Volker$$b26
000851907 7001_ $$aWemeau, Mathieu$$b27
000851907 7001_ $$aDe Wit, Maike$$b28
000851907 7001_ $$aNiemann, Dirk$$b29
000851907 7001_ $$aBonmati, Caroline$$b30
000851907 7001_ $$aSchwänen, Carsten$$b31
000851907 7001_ $$aAbraham, Julie$$b32
000851907 7001_ $$aAljijakli, Ahmad$$b33
000851907 7001_ $$aHaiat, Stephanie$$b34
000851907 7001_ $$aKrämer, Alwin$$b35
000851907 7001_ $$aReichle, Albrecht$$b36
000851907 7001_ $$aGnadler, Martina$$b37
000851907 7001_ $$aWillekens, Christophe$$b38
000851907 7001_ $$aSpiekermann, Karsten$$b39
000851907 7001_ $$aHiddemann, Wolfgang$$b40
000851907 7001_ $$aMüller-Tidow, Carsten$$b41
000851907 7001_ $$aThiede, Christian$$b42
000851907 7001_ $$aRöllig, Christoph$$b43
000851907 7001_ $$aServe, Hubert$$b44
000851907 7001_ $$aBornhäuser, Martin$$b45
000851907 7001_ $$aBaldus, Claudia D.$$b46
000851907 7001_ $$aLengfelder, Eva$$b47
000851907 7001_ $$aFenaux, Pierre$$b48
000851907 7001_ $$aPlatzbecker, Uwe$$b49
000851907 7001_ $$aAdès, Lionel$$b50
000851907 77318 $$2Crossref$$3journal-article$$a10.3324/haematol.2021.278722$$bFerrata Storti Foundation (Haematologica)$$d2021-05-27$$n12$$p3100-3106$$tHaematologica$$v106$$x1592-8721$$y2021
000851907 773__ $$0PERI:(DE-600)2805244-4$$a10.3324/haematol.2021.278722$$n12$$p3100-3106$$tHaematologica$$v106$$x1592-8721$$y2021
000851907 8564_ $$uhttps://publications.rwth-aachen.de/record/851907/files/851907.pdf$$yOpenAccess
000851907 909CO $$ooai:publications.rwth-aachen.de:851907$$popenaire$$popen_access$$pdriver$$pdnbdelivery$$pVDB
000851907 9141_ $$y2021
000851907 9151_ $$0StatID:(DE-HGF)0031$$2StatID$$aPeer reviewed article$$x0
000851907 915__ $$0LIC:(DE-HGF)CCBYNC4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial CC BY-NC 4.0
000851907 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review$$d2020-06-12
000851907 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index$$d2020-06-12
000851907 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-06-12
000851907 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-06-12
000851907 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-06-12
000851907 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-06-12
000851907 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-06-12
000851907 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-06-12
000851907 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-06-12
000851907 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-06-12
000851907 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-06-12
000851907 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-06-12
000851907 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000851907 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$f2020-06-12
000851907 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-06-12
000851907 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2020-06-12
000851907 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-06-12
000851907 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-06-12
000851907 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-06-12
000851907 9201_ $$0I:(DE-82)531040-2_20140620$$k531040-2$$lKlinik und Lehrstuhl für Innere Medizin (mit dem Schwerpunkt Onkologie und Hämatologie)$$x0
000851907 961__ $$z2022-11-02
000851907 970__ $$aeva483339
000851907 9801_ $$aFullTexts
000851907 980__ $$aI:(DE-82)531040-2_20140620
000851907 980__ $$aUNRESTRICTED
000851907 980__ $$aVDB
000851907 980__ $$ajournal
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/cncr.11636$$uShih LY, Kuo MC, Liang DC. Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia. Cancer. 2003; 98(6):1206-1216.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/cncr.27650$$uZhang Y, Zhang Z, Li J. Long-term efficacy and safety of arsenic trioxide for firstline treatment of elderly patients with newly diagnosed acute promyelocytic leukemia. Cancer. 2013; 119(1):115-125.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1007/BF02782196$$uPantic M, Novak A, Marisavljevic D. Additional chromosome aberrations in acute promyelocytic leukemia: characteristics and prognostic influence. Med Oncol. 2000; 17(4):307-313.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1007/s00277-014-2142-9$$uLucena-Araujo AR, Kim HT, Jacomo RH. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline- based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. Ann Hematol. 2014; 93(12):2001-2010.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1007/s00277-016-2622-1$$uTesta U, Lo-Coco F. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients. Ann Hematol. 2016; 95(5):673-680.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/0197-2456(96)00075-X$$uSchemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996; 17(4):343-346.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/S0165-4608(96)90076-X$$uMitelman F. ISCN: An International System for Human Cytogenetic Nomenclature. 1995.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/S1470-2045(15)00193-X$$uBurnett AK, Russell NH, Hills RK. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015; 16(13):1295-1305.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.beha.2014.04.006$$uLo-Coco F, Hasan SK. Understanding the molecular pathogenesis of acute promyelocytic leukemia. Best Pract Res Clin Haematol. 2014; 27(1):3-9.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.blre.2017.09.001$$uJillella AP, Kota VK. The global problem of early deaths in acute promyelocytic leukemia: a strategy to decrease induction mortality in the most curable leukemia. Blood Rev. 2018; 32(2):89-95.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.leukres.2009.08.001$$uKiguchi T, Yoshino Y, Yuan B. Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia. Leuk Res. 2010; 34(3):403-405.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.leukres.2013.07.030$$uLou Y, Suo S, Tong H. Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy. Leuk Res. 2013; 37(11):1451-1456.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1038/leu.2014.240$$uRahmé R, Thomas X, Recher C. Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients. Leukemia. 2014; 28(12):2422-2424.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1038/leu.2016.122$$uCicconi L, Divona M, Ciardi C. PMLRARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy. Leukemia. 2016; 30(10):1987-1992.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1038/leu.2017.71$$uLehmann S, Deneberg S, Antunovic P. Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997-2013. Leukemia. 2017; 31(6):1457-1459.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1038/s41375-018-0139-4$$uKayser S, Schlenk RF, Platzbecker U. Management of patients with acute promyelocytic leukemia. Leukemia. 2018; 32(6):1277-1294.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1038/s41375-020-0758-4$$uKayser S, Rahmé R, Martínez-Cuadrón D. Outcome of older (70 years) APL patients frontline treated with or without arsenic trioxide- an International Collaborative Study. Leukemia. 2020; 34(9):2333-2341.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1038/sj.leu.2400756$$uKiyoi H, Naoe T, Yokota S. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia. 1997; 11(9):1447-1452.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1038/sj.leu.2400812$$uYokota S, Kiyoi H, Nakao M. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia. 1997; 11(10):1605-1609.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1038/sj.leu.2402723$$uNoguera NI, Breccia M, Divona M. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia. 2002; 16(11):2185-2189.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1038/sj.leu.2403766$$uSchlenk RF, Germing U, Hartmann F. High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia. 2005; 19(6):978-983.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1053/shem.2002.33610$$uDavison K, Mann KK, Miller WH, Davison K. Arsenic trioxide: mechanisms of action. Semin Hematol. 2002; 39(2 Suppl 1):3-7.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1056/NEJMoa1300874$$uLo-Coco F, Avvisati G, Vignetti M. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013; 369(2):111-121.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1073/pnas.0813280106$$uHu J, Liu YF, Wu CF. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2009; 106(9):3342-3347.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1080/01621459.1958.10501452$$uKaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53(282):457-481.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1111/bjh.12931$$uPaulson K, Serebrin A, Lambert P. Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study. Br J Haematol. 2014; 166(5):660-666.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1111/j.1365-2141.2000.02442.x$$uDe Botton S, Chevret S, Sanz M. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol. 2000; 111(3):801-806.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1182/blood-2002-03-0886$$uPagano L, Pulsoni A. Second malignancy after treatment of acute promyelocytic leukemia: experience of GIMEMA trials. Blood. 2002; 100(4):1514-1515.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1182/blood-2007-07-100669$$ude la Serna J, Montesinos P, Vellenga E. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with alltrans retinoic acid and idarubicin. Blood. 2008; 11(7):3395-4302.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1182/blood-2010-02-269621$$uPowell BL, Moser B, Stock W. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010; 116(19):3751-3757.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1182/blood-2010-03-276196$$uLo-Coco F, Avvisati G, Vignetti M. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA- 2000 trial of the GIMEMA group. Blood. 2010; 116(17):3171-3179.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1182/blood-2011-04-346437$$uPark JH, Qiao B, Panageas KS. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood. 2011; 118(5):1248-1254.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1182/blood-2016-02-699439$$uZhu H, Hu J, Chen L. The 12-year follow- up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia. Blood. 2016; 128(11):1525-1528.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1182/blood-2019-01-894980$$uSanz MA, Fenaux P, Tallman MS. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019; 133(15):1630-1643.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1182/blood.V99.12.4326$$uThiede C, Steudel C, Mohr B. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002; 99(12):4326-4335.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1200/JCO.2003.04.036$$uCheson BD, Bennett JM, Kopecky KJ. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003; 21(24):4642-4649.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1200/JCO.2010.29.2268$$uMontesinos P, González JD, González J. Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic acid and anthracycline-based chemotherapy. J Clin Oncol. 2010; 28(24):3872-3879.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1200/JCO.2010.32.2107$$uGhavamzadeh A, Alimoghaddam K, Rostami S. Phase II study of singleagent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol. 2011; 29(20):2753-2757.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1200/JCO.2016.67.1982$$uPlatzbecker U, Avvisati G, Cicconi L. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. J Clin Oncol. 2016; 35(6):605-612.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1214/aos/1176350951$$uGray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 16(3):1141-1154.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.3109/10428194.2013.842985$$uPoiré X, Moser BK, Gallagher RE. Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. Leuk Lymphoma. 2014; 55(7):1523-1532.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.3324/haematol.2009.013243$$uCervera J, Montesinos P, Hernández-Rivas JM. Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Haematologica. 2010; 95(3):424-431.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.3390/cancers11101591$$uNoguera NI, Catalano G, Banella C. Acute promyelocytic leukemia: update on the mechanisms of leukemogenesis, resistance and on innovative treatment strategies. Cancers. 2019; 11(10):1591.
000851907 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.7326/0003-4819-103-4-620$$uBennett JM, Catovsky D, Daniel MT. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985; 103(4):620-625.
000851907 999C5 $$2Crossref$$uR Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria. 2014.
000851907 999C5 $$2Crossref$$uSwerdlow SH, Campo E, Harris NL. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th edition. 2017.